Skip to content

Innoviva, Inc.

INVA· NasdaqCore metricsCIK 1080014

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · +0.61%
Market cap
$1.35B
71.08M shares
Filings
1,014
$106.12M
Q3 2026+14.7% FY25 yoy
-$73.89M
Q3 2026+1,059.2% FY25 yoy
$42.15M
Q3 2026−1.9% FY25 yoy
$128.01M
Q3 2026derived+3.9% FY25 yoy
-$1.03
Q3 2026+816.7% FY25 yoy
$581.39M
Q3 2026+80.7% FY25 yoy
$1.35B
7.0×
3.1×
1.2×
13.53%
—

Twelve months to Sep 30, 2026 · derived

Price

$18.9813.29%$2.91past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$411.33MFY 2025
$411.33M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$411,328,000reported
FY 20242024-12-31$358,711,000reported
FY 20232023-12-31$310,463,000reported
FY 20222022-12-31$331,339,000reported
FY 20212021-12-31$391,866,000reported
FY 20202020-12-31$336,794,000reported
FY 20192019-12-31$261,016,000reported
FY 20182018-12-31$261,004,000reported
FY 20172017-12-31$217,217,000reported
FY 20162016-12-31$133,569,000reported
FY 20152015-12-31$53,949,000reported
FY 20142014-12-31$8,433,000reported

Capital returns

Dividends and buybacks · FY2012 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$4.53M$4.53M—74.07M sh+18.2%2.3%
FY2024—$14.78M$14.78M—62.68M sh−0.9%7.8%
FY2023—$75.73M$75.73M—63.23M sh−7.2%53.8%
FY2022—$8.50M$8.50M—68.13M sh−2.1%4.2%
FY2021$0.00$394.15M$394.15M—69.57M sh−31.4%108.3%

Segments

Cost of revenue by Geography, FY2022 to FY2025FY2022United States · FY2022 · $2.49MRest of the world · FY2022 · $1.28MFY2023United States · FY2023 · $41.04MRest of the world · FY2023 · $6.34MFY2024United States · FY2024 · $36.60MRest of the world · FY2024 · $11.86MFY2025United States · FY2025 · $77.38M
LineFY2025ShareChange
United States$77.38M100%+111.4%
Rest of the world———
Total$77.38M

From the 10-K filed Feb 25, 2026INVA

Pharmaceutical preparations

Innoviva, Inc. is the 60th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Innoviva, Inc. · CIK 1080014 · Engraved from SEC EDGAR